company background image
688136 logo

Kexing Biopharm SHSE:688136 Stock Report

Last Price

CN¥19.80

Market Cap

CN¥3.9b

7D

11.0%

1Y

2.4%

Updated

23 Dec, 2024

Data

Company Financials +

Kexing Biopharm Co., Ltd.

SHSE:688136 Stock Report

Market Cap: CN¥3.9b

688136 Stock Overview

Engages in the research and development, production, and sale of recombinant protein drugs and microbial preparations in China and internationally. More details

688136 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health2/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Kexing Biopharm Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Kexing Biopharm
Historical stock prices
Current Share PriceCN¥19.80
52 Week HighCN¥22.82
52 Week LowCN¥10.61
Beta0.84
1 Month Change19.57%
3 Month Change36.74%
1 Year Change2.43%
3 Year Change-29.66%
5 Year Changen/a
Change since IPO-51.72%

Recent News & Updates

There's No Escaping Kexing Biopharm Co., Ltd.'s (SHSE:688136) Muted Revenues Despite A 36% Share Price Rise

Oct 08
There's No Escaping Kexing Biopharm Co., Ltd.'s (SHSE:688136) Muted Revenues Despite A 36% Share Price Rise

Recent updates

There's No Escaping Kexing Biopharm Co., Ltd.'s (SHSE:688136) Muted Revenues Despite A 36% Share Price Rise

Oct 08
There's No Escaping Kexing Biopharm Co., Ltd.'s (SHSE:688136) Muted Revenues Despite A 36% Share Price Rise

Kexing Biopharm Co., Ltd.'s (SHSE:688136) Share Price Boosted 36% But Its Business Prospects Need A Lift Too

May 21
Kexing Biopharm Co., Ltd.'s (SHSE:688136) Share Price Boosted 36% But Its Business Prospects Need A Lift Too

Shandong Kexing Bioproducts Co,.Ltd (SHSE:688136) Held Back By Insufficient Growth Even After Shares Climb 25%

Mar 08
Shandong Kexing Bioproducts Co,.Ltd (SHSE:688136) Held Back By Insufficient Growth Even After Shares Climb 25%

Shareholder Returns

688136CN BiotechsCN Market
7D11.0%-1.9%-1.2%
1Y2.4%-16.2%11.8%

Return vs Industry: 688136 exceeded the CN Biotechs industry which returned -16.2% over the past year.

Return vs Market: 688136 underperformed the CN Market which returned 11.8% over the past year.

Price Volatility

Is 688136's price volatile compared to industry and market?
688136 volatility
688136 Average Weekly Movement8.4%
Biotechs Industry Average Movement8.8%
Market Average Movement8.7%
10% most volatile stocks in CN Market12.8%
10% least volatile stocks in CN Market5.7%

Stable Share Price: 688136 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 688136's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19891,014Yanqing Zhaowww.kexing.com

Kexing Biopharm Co., Ltd. engages in the research and development, production, and sale of recombinant protein drugs and microbial preparations in China and internationally. The company focuses on pharmaceutical research in the therapeutic fields of antiviral, tumor and immunity, blood, digestion, and degenerative diseases. Its products include recombinant human interferon a1b, human erythropoietin, and human granulocyte stimulating factor; Clostridium butyricum combined live bacteria powder; Kehuang Capsule, a Chinese patent medicine; Entecavir, a chemical drug; and liraglutide, a human glucagon-like peptide-1, as well as Albumin-Paclitaxel, Infliximab, Bevacizumab, adalimumab, trastuzumab, neratinib maleate tablets, and lenalidomide capsules.

Kexing Biopharm Co., Ltd. Fundamentals Summary

How do Kexing Biopharm's earnings and revenue compare to its market cap?
688136 fundamental statistics
Market capCN¥3.91b
Earnings (TTM)-CN¥118.80m
Revenue (TTM)CN¥1.33b

2.9x

P/S Ratio

-32.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688136 income statement (TTM)
RevenueCN¥1.33b
Cost of RevenueCN¥407.21m
Gross ProfitCN¥921.08m
Other ExpensesCN¥1.04b
Earnings-CN¥118.80m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.60
Gross Margin69.34%
Net Profit Margin-8.94%
Debt/Equity Ratio69.9%

How did 688136 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 03:36
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kexing Biopharm Co., Ltd. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kai WangCitic Securities Co., Ltd.
Yin YePing An Securities Co. Ltd.
Song YangTianfeng Securities Brokerage Co., Ltd